NASDAQ: ALNY
Alnylam Pharmaceuticals Inc Stock Ownership - Who owns Alnylam Pharmaceuticals?

Insider buying vs selling

Have Alnylam Pharmaceuticals Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Pushkal GargEVP Chief RD2025-08-19260$459.59
$119.49kSell
Pushkal GargEVP Chief RD2025-08-19305$461.01
$140.61kSell
Pushkal GargEVP Chief RD2025-08-1945$461.74
$20.78kSell
Pushkal GargEVP Chief RD2025-08-19276$455.41
$125.69kSell
Pushkal GargEVP Chief RD2025-08-19338$457.26
$154.55kSell
Pushkal GargEVP Chief RD2025-08-19231$458.27
$105.86kSell
Pushkal GargEVP Chief RD2025-08-18103$451.99
$46.55kSell
Pushkal GargEVP Chief RD2025-08-1890$449.92
$40.49kSell
Pushkal GargEVP Chief RD2025-08-1839$447.98
$17.47kSell
Michael W. BonneyDirector2025-08-1811,250$70.20
$789.75kBuy

1 of 29

ALNY insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when ALNY insiders and whales buy or sell their stock.

ALNY Shareholders

What type of owners hold Alnylam Pharmaceuticals Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Capital World Investors12.82%16,805,007$7.60BInstitution
Fmr LLC12.06%15,806,521$7.15BInstitution
Ag Novartis11.29%14,800,620$6.69BInsider
Vanguard Group Inc10.14%13,297,139$6.01BInstitution
Sanofi8.05%10,554,134$4.77BInsider
Blackrock Inc7.61%9,980,163$4.51BInstitution
Capital Research Global Investors5.49%7,191,656$3.25BInstitution
Regeneron Pharmaceuticals Inc3.39%4,444,445$2.01BInstitution
T Rowe Price Investment Management Inc3.27%4,281,279$1.94BInstitution
Dodge Cox2.44%3,197,096$1.45BInstitution

1 of 3

ALNY vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
ALNY82.80%17.20%Net SellingNet Selling
REGN68.94%31.06%Net Selling
ARGX52.63%0.00%
ONC2.41%32.43%Net SellingNet Selling
INSM84.81%15.19%Net SellingNet Selling

Alnylam Pharmaceuticals Stock Ownership FAQ

Who owns Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals (NASDAQ: ALNY) is owned by 101.83% institutional shareholders, 21.15% Alnylam Pharmaceuticals insiders, and 0.00% retail investors. Ag Novartis is the largest individual Alnylam Pharmaceuticals shareholder, owning 14.80M shares representing 11.29% of the company. Ag Novartis's Alnylam Pharmaceuticals shares are currently valued at $6.61B.

If you're new to stock investing, here's how to buy Alnylam Pharmaceuticals stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.